News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Generate Biomedicines (GENB) is projected to experience a decline in earnings at 10.7% annually, despite an expected 41% annual revenue growth and a 1.6% EPS growth. The company, which is focused on AI-driven drug discovery with a $1.8 billion market cap, faces significant risks …
Generate Biomedicines Inc. has released its financial results for the second quarter of 2026 and provided a business update. This report details the company's financial performance and outlines recent developments and strategic initiatives.
Generate Biomedicines, Inc. reported Q2 2026 results with revenue of $6.3M, a 37.7% decline year-over-year, and a net loss of $67.3M, or diluted EPS of $(0.52). The company saw reduced collaboration revenue as partner obligations neared completion but advanced several clinical programs including GB-0895 …
Generate Biomedicines reported its second-quarter 2026 results, showing $6.3 million in collaboration revenue and a net loss of $67.3 million. The company held $457.4 million in cash, which is expected to fund operations into the first half of 2028, and highlighted advancement in multiple …
Generate Biomedicines (GENB) shares dropped by 4.6% after the company announced its Q2 financial results, indicating a wider loss than expected. The full details of the financial performance are behind a premium paywall.
Generate Biomedicines (GENB) is utilizing machine learning for drug discovery and development, holding a market cap of US$1.8 billion. While revenue is projected to grow significantly, the company is currently unprofitable and faces risks such as declining earnings forecasts and a cash runway of …
Generate Biomedicines (NASDAQ: GENB) is one of the top five largest holdings of Nvidia (NASDAQ: NVDA), run by CEO Jensen Huang. Let that sink in for a moment. The largest publicly traded company by market capitalization has roughly $10.4 million invested in a clinical-stage …
Search by ticker symbol or company name and select a result to open its chart.